Day One Biopharmaceuticals (NASDAQ:DAWN) Given “Buy” Rating at Needham & Company LLC

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $33.00 price objective on the stock. Needham & Company LLC’s price objective indicates a potential upside of 115.83% from the stock’s current price.

DAWN has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Friday. Piper Sandler reiterated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Day One Biopharmaceuticals Stock Down 0.5 %

Shares of DAWN stock traded down $0.07 during mid-day trading on Tuesday, hitting $15.29. 1,481,532 shares of the company’s stock were exchanged, compared to its average volume of 892,022. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -6.10 and a beta of -1.51. The stock has a 50-day simple moving average of $14.00 and a two-hundred day simple moving average of $14.83. Day One Biopharmaceuticals has a fifty-two week low of $9.67 and a fifty-two week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). As a group, analysts anticipate that Day One Biopharmaceuticals will post -2.69 earnings per share for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 70,051 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the sale, the chief executive officer now owns 651,762 shares of the company’s stock, valued at $11,653,504.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Charles N. York II sold 52,183 shares of Day One Biopharmaceuticals stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the sale, the chief financial officer now directly owns 225,571 shares of the company’s stock, valued at $4,035,465.19. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 70,051 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the transaction, the chief executive officer now owns 651,762 shares in the company, valued at approximately $11,653,504.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 195,534 shares of company stock worth $3,367,830. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of DAWN. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $29,000. Quintet Private Bank Europe S.A. grew its holdings in Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter worth about $113,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Day One Biopharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after purchasing an additional 7,841 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $156,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.